For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$920.69
Thesis
Regeneron pairs a durable, cash-generative Eylea retinal franchise with a fast-growing Dupixent business co-developed with Sanofi across atopic and inflammatory indications. The pipeline extends into oncology (Libtayo and bispecifics) and obesity-adjacent metabolic assets.
The franchise has the rare combination of high quality earnings and an active, internally discovered pipeline — biosimilar pressure on Eylea is the main overhang, with Eylea HD partly mitigating it.
Catalysts
- Eylea HD share gains slowing biosimilar erosion
- Dupixent indication expansions (COPD and beyond)
- Oncology readouts across the bispecific antibody pipeline
- Capital deployment given the strong cash position
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Oct 30Financial resultsSEC
8-K filing (items 2.02, 9.01) disclosing financial results and exhibits.
- Oct 6OtherSEC
8-K filing with items 1.01 (material agreement), 2.02 (financial condition), and 8.01 (other events).
- Sep 30LeadershipSEC
8-K filing with items 5.02 and 9.01 disclosing officer departure or appointment.
- Jul 30Financial resultsSEC
8-K filed with items 2.02 and 9.01 disclosing financial results.
- Jul 6Financial resultsSEC
Regeneron filed Form 8-K item 2.02 on results of operations and financial condition.